뉴론 파마슈티컬스, ENIGMA-TRS 지원을 위해 3,800만 유로 투자 유치

Newron Pharmaceuticals has announced an equity issuance of up to €38m with a group of existing and new shareholders from Europe and Asia. Proceeds will be used to support the company’s Phase III ENIGMA-TRS programme, assessing lead asset evenamide in treatment-resistant schizophrenia (TRS). Importantly, this provides increased operational flexibility as Newron continues to progress evenamide through Phase III, with ENIGMA-TRS 1 and ENIGMA-TRS 2 top-line readouts expected in Q426. We believe this investment from both existing and new shareholders adds confidence in evenamide’s potential to address TRS, an underserved subpopulation of schizophrenia with limited treatment options at present. Should the outcome of ENIGMA-TRS be positive, it could lead to evenamide becoming the first add-on therapy for TRS, representing an important breakthrough in the field, in our view.